Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors

Detalles Bibliográficos
Autor principal: Ferrucci, Pier Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170280/
https://www.ncbi.nlm.nih.gov/pubmed/37181342
http://dx.doi.org/10.21037/atm-23-341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170280/
https://www.ncbi.nlm.nih.gov/pubmed/37181342
http://dx.doi.org/10.21037/atm-23-341

Ejemplares similares